Contraindications: Not intended for use by individuals under 18 years of age. Persons with pre-existing hepatic conditions, cardiovascular disease, hormonal disorders, or active SARM/androgen sensitivity should not use this product. Pregnancy and breastfeeding are absolute contraindications.
Side Effects: Dose-dependent testosterone suppression is the primary risk in SARM stack cycles, with multi-compound protocols (particularly those including LGD-4033 and RAD-140) carrying greater suppression potential than mono-compound use. Other reported effects include transient headache, fatigue during the mid-cycle suppression window, and mild lipid profile changes (reduction in HDL). Hepatotoxic risk is lower than with 17-alpha alkylated compounds but cannot be dismissed at elevated doses.
Monitoring: Obtain baseline and end-of-cycle bloodwork including LH, FSH, total testosterone, SHBG, and a lipid panel. Liver enzyme markers (AST/ALT) should be assessed if cycles exceed 8 weeks or compounds with hepatic concern are stacked. Blood pressure monitoring is advisable during LGD+RAD bulking stacks.
PCT: A structured post-cycle therapy using a selective estrogen receptor modulator (SERM such as Nolvadex or Clomid) is recommended following any suppressive multi-SARM stack. Duration of PCT (typically 4–6 weeks) should be calibrated to post-cycle testosterone bloodwork rather than fixed to a standard protocol.